Innate Pharma S.A./€IPH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Innate Pharma S.A.
Innate Pharma S.A. is a clinical-stage biotechnology company specializing in immuno-oncology, focusing on developing therapeutic antibodies that engage the innate immune system to treat cancer. Its pipeline includes lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous and peripheral T-cell lymphomas, and monalizumab, an immune checkpoint inhibitor in Phase III trials for advanced solid tumors. Founded in 1999 and headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, the company has established collaborations with biopharmaceutical firms such as AstraZeneca and Sanofi. Innate Pharma's proprietary ANKET® platform focuses on developing multi-specific NK cell engagers, positioning the company in the field of natural killer cell therapeutics.
- Ticker
- €IPH
- Sector
- Health
- Primary listing
- PAR
- Employees
- 120
- Headquarters
- Marseille, France
- Website
- www.innate-pharma.com
IPH Metrics
BasicAdvanced
€130M
-
-€0.51
0.88
-
Price and volume
Market cap
€130M
Beta
0.88
52-week high
€2.33
52-week low
€1.04
Average daily volume
226K
Financial strength
Current ratio
0.597
Quick ratio
0.471
Long term debt to equity
-0.232
Total debt to equity
-0.499
Interest coverage (TTM)
-124.92%
Profitability
EBITDA (TTM)
-46.962
Gross margin (TTM)
-307.60%
Net profit margin (TTM)
-483.85%
Operating margin (TTM)
-485.25%
Revenue per employee (TTM)
€80,000
Management effectiveness
Return on assets (TTM)
-46.60%
Return on equity (TTM)
268.39%
Valuation
Price to revenue (TTM)
13.166
Price to book
-3.21
Price to tangible book (TTM)
-3.21
Price to free cash flow (TTM)
-3.017
Free cash flow yield (TTM)
-33.15%
Free cash flow per share (TTM)
-0.46
Growth
Revenue change (TTM)
-22.38%
Earnings per share change (TTM)
-6.97%
3-year revenue growth (CAGR)
-42.75%
10-year revenue growth (CAGR)
-13.37%
3-year earnings per share growth (CAGR)
-13.54%
10-year earnings per share growth (CAGR)
28.70%
What the Analysts think about IPH
Analyst ratings (Buy, Hold, Sell) for Innate Pharma S.A. stock.
Analyst projections of the future price of Innate Pharma S.A. stock.
IPH Financial Performance
Revenues and expenses
IPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.